Renal studies provide an insight into cardiac extracellular matrix remodeling during health and disease

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 3, 2010, Pages 497-503

  Hertig, Alexandre ^a   Gangadhar, Taduri ^a   Kalluri, Raghu ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Department of Biological Chemistry and Molecular Pharmacology ^*  (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Acute kidney injury; Endothelial to mesenchymal transition; Epithelial to mesenchymal transition; Extra cellular matrix; Fibrosis; Heart remodeling; Integrin; PAI 1; TPA; Transforming growth factor beta

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

CELL ADHESION; CELL HYPOXIA; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL DIFFERENTIATION; ENDOTHELIAL CELLS; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; KIDNEY; MESODERM; MODELS, BIOLOGICAL; MYOCARDIUM;

EID: 77649273257     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.07.022     Document Type: Review

References (50)

1. Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 2008, 52:1527-1539.
2. Berl T., Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin. J. Am. Soc. Nephrol. 2006, 1:8-18.
3. Anavekar N.S., McMurray J.J., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.L., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 2004, 351:1285-1295.
4. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351:1296-1305.
5. Boffa J.J., Lu Y., Placier S., Stefanski A., Dussaule J.C., Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol. 2003, 14:1132-1144.
6. Kumar R., Singh V.P., Baker K.M. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr. Opin. Nephrol. Hypertens. 2008, 17:168-173.
7. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992, 327:669-677.
8. Thadhani R., Pascual M., Bonventre J.V. Acute renal failure. N. Engl. J. Med. 1996, 334:1448-1460.
9. Humar A., Ramcharan T., Kandaswamy R., Gillingham K., Payne W.D., Matas A.J. Risk factors for slow graft function after kidney transplants: a multivariate analysis. Clin. Transplant. 2002, 16:425-429.
10. Lindsey M.L. MMP induction and inhibition in myocardial infarction. Heart. Fail. Rev. 2004, 9:7-19.
11. Yang J., Shultz R.W., Mars W.M., Wegner R.E., Li Y., Dai C., et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J. Clin. Invest. 2002, 110:1525-1538.
12. Kassiri Z., Oudit G.Y., Kandalam V., Awad A., Wang X., Ziou X., et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 2009, 20:1223-1235.
13. Serruys P.W., Morice M.C., Kappetein A.P., Colombo A., Holmes D.R., Mack M.J., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009.
14. Preston R.A., Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J. Hypertens. 1997, 15:1365-1377.
15. Ishani A., Xue J.L., Himmelfarb J., Eggers P.W., Kimmel P.L., Molitoris B.A., et al. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 2009, 20:223-228.
16. Zeisberg M., Strutz F., Muller G.A. Role of fibroblast activation in inducing interstitial fibrosis. J. Nephrol. 2000, 13(Suppl 3):S111-120.
17. Neilson E.G. Mechanisms of disease: fibroblasts-a new look at an old problem. Nat. Clin. Pract. Nephrol. 2006, 2:101-108.
18. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009, 119:1438-1449.
19. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
20. Zeisberg M., Bottiglio C., Kumar N., Maeshima Y., Strutz F., Muller G.A., et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal. Physiol. 2003, 285:F1060-1067.
21. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002, 110:341-350.
22. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
23. Rastaldi M.P., Ferrario F., Giardino L., Dell'Antonio G., Grillo C., Grillo P., et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney. Int. 2002, 62:137-146.
24. Vongwiwatana A., Tasanarong A., Rayner D.C., Melk A., Halloran P.F. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am. J. Transplant. 2005, 5:1367-1374.
25. Hertig A., Verine J., Mougenot B., Jouanneau C., Ouali N., Sebe P., et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am. J. Transplant. 2006, 6:2937-2946.
26. Hertig A., Anglicheau D., Verine J., Pallet N., Touzot M., Ancel P.Y., et al. Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 2008, 19:1584-1591.
27. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
28. Neilson E.G. Plasticity, nuclear diapause, and a requiem for the terminal differentiation of epithelia. J. Am. Soc. Nephrol. 2007, 18:1995-1998.
29. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell. Biol. 2004, 5:343-354.
30. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007, 117:3810-3820.
31. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006, 17:17-25.
32. Sampson N.S., Ryan S.T., Enke D.A., Cosgrove D., Koteliansky V., Gotwals P. Global gene expression analysis reveals a role for the alpha 1 integrin in renal pathogenesis. J. Biol. Chem. 2001, 276:34182-34188.
33. Hannigan G.E., Leung-Hagesteijn C., Fitz-Gibbon L., Coppolino M.G., Radeva G., Filmus J., et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
34. Hu K., Wu C., Mars W.M., Liu Y. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J. Clin. Invest. 2007, 117:3821-3832.
35. Hu K., Lin L., Tan X., Yang J., Bu G., Mars W.M. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J. Am. Soc. Nephrol. 2008, 19:503-514.
36. Edgtton K.L., Gow R.M., Kelly D.J., Carmeliet P., Kitching A.R. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney. Int. 2004, 66:68-76.
37. Luttun A., Lupu F., Storkebaum E., Hoylaerts M.F., Moons L., Crawley J., et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:499-505.
38. Hertig A., Berrou J., Allory Y., Breton L., Commo F., Costa De Beauregard M.A., et al. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. Faseb. J. 2003, 17:1904-1906.
39. Gaertner R., Jacob M.P., Prunier F., Angles-Cano E., Mercadier J.J., Michel J.B. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J. Mol. Cell. Cardiol. 2005, 38:193-204.
40. Hahm K., Lukashev M.E., Luo Y., Yang W.J., Dolinski B.M., Weinreb P.H., et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 2007, 170:110-125.
41. Rinn J.L., Bondre C., Gladstone H.B., Brown P.O., Chang H.Y. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS. Genet. 2006, 2:e119.
42. Hannigan G.E., Coles J.G., Dedhar S. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 2007, 100:1408-1414.
43. Shai S.Y., Harpf A.E., Babbitt C.J., Jordan M.C., Fishbein M.C., Chen J., et al. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res. 2002, 90:458-464.
44. Lin J., Patel S.R., Cheng X., Cho E.A., Levitan I., Ullenbruch M., et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005, 11:387-393.
45. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003, 9:964-968.
46. Zeisberg M., Yang C., Martino M., Duncan M.B., Rieder F., Tanjore H., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 2007, 282:23337-23347.
47. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 1998, 339:69-75.
48. Assmus B., Honold J., Schachinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 2006, 355:1222-1232.
49. Schachinger V., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., Holschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 2006, 355:1210-1221.
50. Sugimoto H., Mundel T.M., Sund M., Xie L., Cosgrove D., Kalluri R. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7321-7326.